+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cancer Biomarkers Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Biomarker, Type of Cancer and Key Geographical Regions- Product Image
Cancer Biomarkers Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Biomarker, Type of Cancer and Key Geographical Regions- Product Image
New

Cancer Biomarkers Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Biomarker, Type of Cancer and Key Geographical Regions

  • PDF Icon

    Report

  • 309 Pages
  • March 2025
  • Region: Global
  • Roots Analysis
  • ID: 4801463
Description Jump to:

The global cancer biomarkers market is estimated to grow from USD 28.6 billion in 2025, to USD 46.7 billion by 2035, at a CAGR of 5% during the forecast period to 2035.

CANCER BIOMARKERS MARKET: GROWTH AND TRENDS

The clinical success of several immunotherapies, such as checkpoint inhibitors, has already been established across multiple solid tumors. However, there still exists an unmet need related to evaluating the type of therapy that is to be used for treating different individuals suffering from a specific type of cancer. This is attributed to the fact that patients suffering from same cancer (same stage of the disease) may have exhibited different molecular profiles and respond differently to recommended drug / therapy types. In order to achieve better results for the patients, it is critical to identify reliable cancer biomarkers. Biomarkers provide valuable information about the molecular characteristics of individual tumors, allowing clinicians to tailor treatment strategies to each patient's unique profile. 

The future of cancer biomarkers is promising as they have the potential to be used in various aspects of cancer medicine, such as screening, cancer classification, risk assessment, determination of tumor burden, personalization and monitoring of treatment, and prognosis. Moreover, advancements in genomic, proteomic, metabolomic, and microRNomic profiling, along with other techniques, such as comparative genome hybridization (CGH), single nucleotide polymorphism (SNP) analysis, high throughput screening (HTS) and next-generation sequencing (NGS), are paving the way for the discovery of new tumor signatures. Furthermore, the emergence of powerful proteomic and genomic technologies, combined with the analysis of circulating tumor cells (CTC), cancer stem cell-specific markers and cell-free circulating tumor DNA (ctDNA) are contributing to the development of more sensitive and specific biomarkers for early cancer detection, disease progression monitoring and proper treatment selection. Given the ongoing pace of innovation, and increasing interest towards personalized approaches, the cancer biomarkers market is poised to experience a noteworthy growth in the foreseeable future.

CANCER BIOMARKERS MARKET: KEY INSIGHTS

The report delves into the current state of the cancer biomarkers market and identifies potential growth opportunities within the industry. Some key findings from the report include:

  • Presently, close to 100 novel cancer biomarker solutions are available in the market; majority of these solutions use next generation sequencing for the assessment of cancer biomarkers.

  • Stakeholders in this industry are engaged in providing novel cancer biomarker solutions for a wide range of applications; more than 70% of these solutions assist in the evaluation of MSI / MMR.
  • The current market landscape of cancer biomarker testing solution providers is fragmented, featuring the presence of both new entrants and established players; majority of these players are based in the US.
  • Close to 685 clinical trials (with more than 75,000 enrolled patients) are currently ongoing in order to investigate novel cancer biomarkers, across different geographies.
  • The field of cancer biomarkers has seen a significant rise in research, with over 470 articles published by various researchers, underscoring the growing focus of several industry players and academic players in this domain.
  • Driven by the increasing pace of innovation and partnership activity, the market for cancer biomarkers is poised to witness steady growth in the foreseeable future.
  • The cancer biomarkers market is anticipated to grow at a CAGR of 5%, till 2035; North America is expected to capture the majority share (over 45%) of the market by 2035.

Market sizing and opportunity analysis has been segmented across the following parameters:

Type of Biomarker 

  • HER2
  • MET
  • EGFR
  • PD-L1
  • NTRK
  • ALK
  • Novel Biomarkers
  • Other Biomarkers 

Type of Cancer 

  • Breast Cancer
  • Prostate Cancer
  • Colorectum Cancer
  • Lung Cancer
  • Thyroid Cancer
  • Bladder Cancer
  • Melanoma
  • Non-Hodgkins Lymphoma
  • Endometrial Cancer
  • Kidney Cancer
  • Leukemia

Key Geographical Regions

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

CANCER BIOMARKERS MARKET: KEY SEGMENTS

HER2 Biomarker Occupies the Largest Share of the Cancer Biomarkers Market

Based on the type of biomarker, the market is segmented into HER2, MET, EGFR, PD-L1, NTRK, ALK, novel biomarkers and other biomarkers. At present, HER2 biomarkers hold the maximum share of the cancer biomarkers market. It is worth highlighting that the cancer biomarkers market for EGFR is likely to grow at a relatively higher CAGR in the near future.

Breast Cancer is Likely to Dominate the Cancer Biomarkers Market During the Forecast Period

Based on the type of cancer, the market is segmented into breast cancer, prostate cancer, colorectum cancer, lung cancer, thyroid cancer, bladder cancer, melanoma, non-Hodgkins’s lymphoma, endometrial cancer, kidney cancer and leukemia. Currently, breast cancer holds the maximum share of the cancer biomarkers market. This trend is unlikely to change in the near future.

North America Accounts for the Largest Share of the Market

Based on the key geographical regions, the market is segmented into North America, Europe, Asia-Pacific and Rest of the world. Majority share is expected to be captured by players based in North America. It is worth highlighting that, over the years, the market in Asia-Pacific is expected to grow at a higher CAGR.

Sample Players in the Cancer Biomarkers Market Profiled in the Report, Include:

  • Agilent
  • ARUP Laboratories
  • BioReference
  • Foundation Medicine
  • OncoDNA
  • Q² Solutions
  • Thermo Fisher Scientific
  • YuceBio
  • Asper Biogene
  • Caris Life Sciences
  • CeGaT
  • Genekor Medical
  • Guardant Health
  • Labcorp
  • MedGenome
  • NeoGenomics Laboratories
  • Nonacus
  • Oxford Gene Technology
  • Personal Genome Diagnostics
  • PhenoPath
  • Positive Biosciences
  • Quest Diagnostics
  • Tempus

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

  • Chief Technical Officer and Former Director of Preclinical Development & Strategic Partnerships, Large Company, US
  • Business Manager, Mid-sized Company, Germany
  • Former Chief Scientific Officer, Large Company, US

CANCER BIOMARKERS MARKET: RESEARCH COVERAGE

  • Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the cancer biomarkers market, focusing on key market segments, including type of biomarker, type of cancer and geographical regions.
  • Market Landscape: A comprehensive evaluation of testing solutions for novel cancer biomarkers, considering various parameters, such as type of biomarkers, profiling technology used, analytical technique used, turnaround time, sample input, type nucleic acid tested, type of cancer and application area. Additionally, it includes a detailed list of developers engaged in offering novel cancer biomarker testing solutions, along with analysis based on various parameters, such as year of establishment, company size (in terms of employee count) and location of headquarters.
  • Product Competitiveness Analysis: A comprehensive competitive analysis of novel cancer biomarker testing solutions, examining factors, such as product versatility and product competitiveness.
  • Company Profiles: In-depth profiles of key industry players offering novel cancer biomarker testing solutions, focusing on company overviews, financial information, cancer biomarker testing solutions portfolio, recent developments and an informed future outlook.
  • Case Study: A general discussion on the innovative study designs involved in conducting biomarker-based clinical trial to evaluate drugs for oncological disorders. It includes details on the structure of each study design, highlighting their respective advantages and challenges.
  • Clinical Trial Analysis: Examination of completed, ongoing, and planned clinical studies of various novel cancer biomarkers based on parameters like trial registration year, trial status, trial phase, enrolled patient population, type of sponsor / collaborator, most active players (in terms of number of registered trials), study design, target therapeutic area and key geographical regions.
  • Publication Analysis: A detailed publication analysis of over 630 articles that have been published since 2019, highlighting the key focus areas of ongoing research related to novel cancer biomarkers. It highlights the prevalent trends based on the year of publication, type of publication, type of cancer, copyright holders, emerging focus areas, most active publishers (in terms of number of publications) and key journals (in terms of journal impact factor and number of articles published).
  • Big Pharma Analysis: A comprehensive examination of various initiatives focused on cancer biomarkers undertaken by major pharmaceutical companies. This analysis includes heat map visualizations that illustrate the distribution of leading pharmaceutical firms, as well as spider web diagrams that compare their initiatives across multiple relevant parameters.
  • Case Study: A comprehensive value chain analysis that explores the various stages involved in the production of companion diagnostics. This includes a discussion on research and development (R&D), clinical assessment of the product, manufacturing and assembly, payer negotiation and marketing activities and the cost distribution across each of the aforementioned stages.
  • Future Growth Opportunities: A detailed discussion on the upcoming opportunities for cancer biomarker testing solution providers in this field that are likely to impact on the evolution of the market in the short to mid-term and mid to long-term.

KEY QUESTIONS ANSWERED IN THIS REPORT

  • How many companies are currently engaged in this market?
  • Which are the leading companies in this market?
  • What are the factors that are likely to influence the evolution of this market?
  • What is the current and future market size?
  • What is the CAGR of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

  • The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
  • Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
  • The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

  • Complimentary PPT Insights Packs
  • Complimentary Excel Data Packs for all Analytical Modules in the Report
  • 10% Free Content Customization
  • Detailed Report Walkthrough Session with Research Team
  • Free Updated report if the report is 6-12 months old or older

 

Table of Contents

1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Research Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Future Estimates
3.2.2. Currency Coverage and Foreign Exchange Rate
3.2.2.1. Major Currencies Affecting the Market
3.2.2.2. Factors Affecting Currency Fluctuations and Foreign Exchange Rates
3.2.2.3. Impact of Foreign Exchange Rate Volatility on the Market
3.2.2.4. Strategies for Mitigating Foreign Exchange Risks
3.2.3. Trade Policies
3.2.3.1. Impact of Trade Barriers on the Market
3.2.3.2. Strategies for Mitigating the Risks associated with Trade Barriers
3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY
5. INTRODUCTION
5.1. Chapter Overview
5.2. An Overview of Cancer Biomarkers
5.2.1. Need for Cancer Biomarkers
5.2.2. Identification of a Candidate Biomarker
5.3. Type of Cancer Biomarkers
5.4. Novel Cancer Biomarkers
5.4.1. Tumor Mutation Burden (TMB)
5.4.1.1. Variation of TMB across Multiple Indications
5.4.1.2. Methods for Measurement of TMB
5.4.1.3. Factors Affecting Measurement of TMB
5.4.1.4. Initiatives for Assessment of TMB as a Potential Biomarker
5.4.2. Microsatellite Instability / Mismatch Repair Deficiency (MSI / MMR)
5.4.2.1. Variation of MSI across Multiple Indications
5.4.2.2. Methods for Measurement of MSI
5.4.3. Single Nucleotide Variants
5.4.3.1. Variation of SNV across Multiple Indications
5.4.3.2. Methods for Measurement of SNV
5.4.4. Copy Number Variants
5.4.4.1. Variation of CNV across Multiple Indications
5.4.4.2. Methods for Measurement of CNV
5.4.5. Tumor Infiltrating Lymphocytes and Other Novel Biomarkers
5.5. Future Perspective

6. MARKET LANDSCAPE
6.1. Chapter Overview
6.2. Cancer Biomarker Testing Solutions: Overall Market Landscape
6.2.1. Analysis by Type of Biomarker
6.2.2. Analysis by Profiling Technology Used
6.2.3. Analysis by Analytical Technique Used
6.2.4. Analysis by Turnaround Time
6.2.5. Analysis by Sample Input
6.2.6. Analysis by Type of Nucleic Acid Tested
6.2.7. Analysis by Type of Cancer
6.2.8. Analysis by Application Area
6.3. Cancer Biomarkers Testing Solutions: Developer Landscape
6.3.1. Analysis by Year of Establishment
6.3.2. Analysis by Company Size
6.3.3. Analysis by Location of Headquarters

7. PRODUCT COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Assumptions and Key Parameters
7.3. Methodology
7.4. Cancer Biomarkers Testing Solutions: Product Competitiveness Analysis
7.4.1. Products Offered by Players Based in North America
7.4.2. Products Offered by Players Based in Europe
7.4.3. Products Offered by Players Based in Asia-Pacific

8. COMPANY PROFILES
8.1. Chapter Overview
8.2. Detailed Profiles of Leading Cancer Biomarker Testing Solutions Providers
8.2.1. Agilent
8.2.1.1. Company Overview
8.2.1.2. Financial Information
8.2.1.3. Cancer Biomarker Testing Solutions Portfolio
8.2.1.4. Recent Developments and Future Outlook
8.2.2. ARUP Laboratories
8.2.2.1. Company Overview
8.2.2.2. Cancer Biomarker Testing Solutions Portfolio
8.2.2.3. Recent Developments and Future Outlook
8.2.3. BioReference
8.2.3.1. Company Overview
8.2.3.2. Cancer Biomarker Testing Solutions Portfolio
8.2.3.3. Recent Developments and Future Outlook
8.2.4. Foundation Medicine
8.2.4.1. Company Overview
8.2.4.2. Cancer Biomarker Testing Solutions Portfolio
8.2.4.3. Recent Developments and Future Outlook
8.2.5. OncoDNA
8.2.5.1. Company Overview
8.2.5.2. Cancer Biomarker Testing Solutions Portfolio
8.2.5.3. Recent Developments and Future Outlook
8.2.6. Q² Solutions
8.2.6.1. Company Overview
8.2.6.2. Cancer Biomarker Testing Solutions Portfolio
8.2.6.3. Recent Developments and Future Outlook
8.2.7. Thermo Fisher Scientific
8.2.7.1. Company Overview
8.2.7.2. Financial Information
8.2.7.3. Cancer Biomarker Testing Solutions Portfolio
8.2.7.4. Recent Developments and Future Outlook
8.2.8. YuceBio
8.2.8.1. Company Overview
8.2.8.2. Cancer Biomarker Testing Solutions Portfolio
8.2.8.3. Recent Developments and Future Outlook
8.3. Short Profiles of Other Leading Cancer Biomarkers Testing Solutions Providers
8.3.1. Asper Biogene
8.3.1.1. Company Overview
8.3.1.2. Cancer Biomarker Testing Solutions Portfolio
8.3.2. Caris Life Sciences
8.3.2.1. Company Overview
8.3.2.2. Cancer Biomarkers Testing Solutions Portfolio
8.3.3. CeGaT
8.3.3.1. Company Overview
8.3.3.2. Cancer Biomarkers Testing Solutions Portfolio
8.3.4. Genekor Medical
8.3.4.1. Company Overview
8.3.4.2. Cancer Biomarkers Testing Solutions Portfolio
8.3.5. Guardant Health
8.3.5.1. Company Overview
8.3.5.2. Cancer Biomarker Testing Solutions Portfolio
8.3.6. Labcorp
8.3.6.1. Company Overview
8.3.6.2. Cancer Biomarker Testing Solutions Portfolio
8.3.7. MedGenome
8.3.7.1. Company Overview
8.3.7.2. Cancer Biomarker Testing Solutions Portfolio
8.3.8. NeoGenomics Laboratories
8.3.8.1. Company Overview
8.3.8.2. Cancer Biomarker Testing Solutions Portfolio
8.3.9. Nonacus
8.3.9.1. Company Overview
8.3.9.2. Cancer Biomarkers Testing Solutions Portfolio
8.3.10. Oxford Gene Technology
8.3.10.1. Company Overview
8.3.10.2. Cancer Biomarkers Testing Solutions Portfolio
8.3.11. Personal Genome Diagnostics
8.3.11.1. Company Overview
8.3.11.2. Cancer Biomarkers Testing Solutions Portfolio
8.3.12. PhenoPath
8.3.12.1. Company Overview
8.3.12.2. Cancer Biomarkers Testing Solutions Portfolio
8.3.13. Positive Biosciences
8.3.13.1. Company Overview
8.3.13.2. Cancer Biomarkers Testing Solutions Portfolio
8.3.14. Quest Diagnostics
8.3.14.1. Company Overview
8.3.14.2. Cancer Biomarkers Testing Solutions Portfolio
8.3.15. Tempus
8.3.15.1. Company Overview
8.3.15.2. Cancer Biomarkers Testing Solutions Portfolio

9. INNOVATIVE STUDY DESIGNS FOR BIOMARKER-BASED CLINICAL TRIALS
9.1. Chapter Overview
9.2. Study Designs for Biomarker-based Clinical Trials
9.2.1. Enrichment Design
9.2.2. All-comers Design
9.2.3. Mixture / Hybrid Design
9.2.4. Adaptive Design
9.3. Regulatory Guidelines for Biomarker-based Clinical Trial Designs

10. CLINICAL TRIAL ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Cancer Biomarkers: Clinical Trial Analysis
10.3.1. Analysis by Trial Registration Year
10.3.2. Analysis by Trial Status
10.3.3. Analysis by Trial Registration Year and Trial Status
10.3.4. Analysis by Trial Phase
10.3.5. Analysis by Trial Registration Year and Trial Phase
10.3.6. Analysis of Enrolled Patient Population by Trial Registration Year
10.3.7. Analysis of Enrolled Patient Population by Trial Phase
10.3.8. Analysis by Type of Sponsor / Collaborator
10.3.9. Most Active Players: Distribution by Number of Registered Trials
10.3.10. Analysis by Study Design
10.3.11. Analysis by Type of Cancer
10.3.12. Analysis of Clinical Trials by Geography
10.3.13. Analysis of Clinical Trials by Trial Status and Geography
10.3.14. Analysis of Enrolled Patient Population by Geography
10.3.15. Analysis of Enrolled Patient Population by Trial Status and Geography

11. PUBLICATION ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Cancer Biomarkers: Publication Analysis
11.3.1. Analysis by Year of Publication
11.3.2. Analysis by Type of Publication
11.3.3. Analysis by Type of Cancer
11.3.4. Analysis by Copyright Holders
11.3.5. Word Cloud: Emerging Focus Areas
11.3.6. Most Active Publishers: Analysis by Number of Publications
11.3.7. Key Journals: Analysis by Number of Publications
11.3.8. Key Journals: Analysis by Impact Factor

12. BIG PHARMA PLAYERS: BENCHMARK ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Big Pharma Players: Benchmarking Analysis
12.3.1. Spider Web Analysis: Abbott
12.3.2. Spider Web Analysis: AbbVie
12.3.3. Spider Web Analysis: Amgen
12.3.4. Spider Web Analysis: AstraZeneca
12.3.5. Spider Web Analysis: Bayer
12.3.6. Spider Web Analysis: Boehringer Ingelheim
12.3.7. Spider Web Analysis: Bristol-Myers Squib
12.3.8. Spider Web Analysis: Eli Lilly
12.3.9. Spider Web Analysis: Gilead
12.3.10. Spider Web Analysis: GlaxoSmithKline
12.3.11. Spider Web Analysis: Merck
12.3.12. Spider Web Analysis: Novartis
12.3.13. Spider Web Analysis: Pfizer
12.3.14. Spider Web Analysis: Roche
12.3.15. Spider Web Analysis: Sanofi
12.4. Concluding Remarks

13. CASE STUDY: ANALYSIS OF VALUE CHAIN IN THE COMPANION DIAGNOSTICS INDUSTRY
13.1. Chapter Overview
13.2. Companion Diagnostics: Value Chain
13.3. Cost Distribution Across the Value Chain
13.3.1. Costs Associated with Research and Product Development
13.3.2. Costs Associated with Manufacturing and Assembly
13.3.3. Costs Associated with Clinical Trials, FDA Approval and Other Administrative Tasks
13.3.4. Costs Associated with Payer Negotiation and KOL Engagement
13.3.5. Costs Associated with Marketing and Sales

14. FUTURE GROWTH OPPORTUNITIES
14.1. Chapter Overview
14.2. Growing Focus on Personalized Medicines
14.3. Extent of Biomarker Testing for Various Oncological Disorders
14.4. Increase in Number of Biomarker-based Clinical Trials
14.5. Increased Adoption of Emerging Analytical Techniques for Biomarker Assessment
14.6. Development of Companion Diagnostic Products

15. GLOBAL CANCER BIOMARKERS MARKET
15.1. Chapter Overview
15.2. Assumptions and Methodology
15.3. Global Cancer Biomarkers Market, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
15.3.1. Scenario Analysis
15.3.1.1. Conservative Scenario
15.3.1.2. Optimistic Scenario
15.4. Key Market Segmentations

16. CANCER BIOMARKERS MARKET, BY TYPE OF BIOMARKER
16.1. Chapter Overview
16.2. Key Assumptions and Methodology
16.3. Cancer Biomarkers Market: Distribution by Type of Biomarker, 2018, 2024 and 2035
16.3.1. Cancer Biomarkers Market for HER2 Biomarkers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
16.3.2. Cancer Biomarkers Market for MET Biomarkers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
16.3.3. Cancer Biomarkers Market for EGFR Biomarkers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
16.3.4. Cancer Biomarkers Market for PD-L1 Biomarkers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
16.3.5. Cancer Biomarkers Market for NTRK Biomarkers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
16.3.6. Cancer Biomarkers Market for ALK Biomarkers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
16.3.7. Cancer Biomarkers Market for Other Biomarkers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
16.3.7.1. Cancer Biomarkers Market: Distribution of Novel Biomarkers, 2018, 2024 and 2035
16.3.7.1.1. Cancer Biomarkers Market for SNV Biomarkers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
16.3.7.1.2. Cancer Biomarkers Market for MSI Biomarkers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
16.3.7.1.3. Cancer Biomarkers Market for CNV Biomarkers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
16.3.7.1.4. Cancer Biomarkers Market for TMB Biomarkers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
16.3.7.1.5. Cancer Biomarkers Market for TIL Biomarkers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
16.4. Data Triangulation and Validation

17. CANCER BIOMARKERS MARKET, BY TYPE OF CANCER
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Cancer Biomarkers Market: Distribution by Type of Cancer, 2018, 2024 and 2035
17.3.1. Cancer Biomarkers Market for Breast Cancer: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
17.3.2. Cancer Biomarkers Market for Prostate Cancer: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
17.3.3. Cancer Biomarkers Market for Colorectum Cancer: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
17.3.4. Cancer Biomarkers Market for Lung Cancer: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
17.3.5. Cancer Biomarkers Market for Thyroid Cancer: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
17.3.6. Cancer Biomarkers Market for Bladder Cancer: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
17.3.7. Cancer Biomarkers Market for Melanoma: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
17.3.8. Cancer Biomarkers Market for Non-Hodgkin Lymphoma: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
17.3.9. Cancer Biomarkers Market for Endometrial Cancer: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
17.3.10. Cancer Biomarkers Market for Kidney Cancer: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
17.3.11. Cancer Biomarkers Market for Leukemia: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
17.4. Data Triangulation and Validation

18. CANCER BIOMARKERS MARKET, BY KEY GEOGRAPHICAL REGIONS
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Cancer Biomarkers Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035
18.3.1. Cancer Biomarkers Market in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
18.3.1.1. Cancer Biomarkers Market in the US: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
18.3.1.2. Cancer Biomarkers Market in Canada: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
18.3.2. Cancer Biomarkers Market in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
18.3.2.1. Cancer Biomarkers Market in the UK: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
18.3.2.2. Cancer Biomarkers Market in Germany: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
18.3.2.3. Cancer Biomarkers Market in France: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
18.3.2.4. Cancer Biomarkers Market in Spain: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
18.3.2.5. Cancer Biomarkers Market in Italy: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
18.3.3. Cancer Biomarkers Market in Aisa-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
18.3.3.1. Cancer Biomarkers Market in China: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
18.3.3.2. Cancer Biomarkers Market in Japan: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
18.3.3.3. Cancer Biomarkers Market in India: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
18.3.3.4. Cancer Biomarkers Market in Australia: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
18.3.3.5. Cancer Biomarkers Market in South Korea: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
18.3.3.6. Cancer Biomarkers Market in New Zealand: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
18.3.4. Cancer Biomarkers Market in Rest of the World: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
18.3.4.1. Cancer Biomarkers Market in Brazil: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
18.3.4.2. Cancer Biomarkers Market in Argentina: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
18.3.4.3. Cancer Biomarkers Market in Chile: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
18.3.4.4. Cancer Biomarkers Market in Egypt: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
18.4. Data Triangulation and Validation

19. CONCLUDING REMARKS
20. EXECUTIVE INSIGHTS
20.1. Chapter Overview
20.2. Cell IDc
20.2.1. Company Snapshot
20.2.2. Interview Transcript: David Schwartz, Chief Technical Officer and Helen Synder, Former Director of Preclinical Development & Strategic Partnerships
20.3. CeGat
20.3.1. Company Snapshot
20.3.2. Interview Transcript: Kirill Shur, Business Manager
20.4. NeoGenomics Laboratories
20.4.1. Company Snapshot
20.4.2. Interview Transcript: Lawrence Weiss, Former Chief Scientific Officer

21. APPENDIX 1: TABULATED DATA22. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
LIST OF FIGURES
Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Forecast Methodology
Figure 2.3 Research Methodology: Robust Quality Control
Figure 2.4 Research Methodology: Key Market Segmentation
Figure 3.1 Lessons Learnt from Past Recessions
Figure 4.1 Executive Summary: Current Market Landscape (I/II)
Figure 4.2 Executive Summary: Current Market Landscape (II/II)
Figure 4.3 Executive Summary: Clinical Trial Analysis
Figure 4.4 Executive Summary: Publication Analysis
Figure 4.5 Executive Summary: Market Forecast and Opportunity Analysis
Figure 6.1 Cancer Biomarker Testing Solutions: Distribution by Type of Biomarker
Figure 6.2 Cancer Biomarker Testing Solutions: Distribution by Profiling Technology Used
Figure 6.3 Cancer Biomarker Testing Solutions: Distribution by Analytical Technique Used
Figure 6.4 Cancer Biomarker Testing Solutions: Distribution by Turnaround Time
Figure 6.5 Cancer Biomarker Testing Solutions: Distribution by Sample Input
Figure 6.6 Cancer Biomarker Testing Solutions: Distribution by Type of Nucleic Acid Tested
Figure 6.7 Cancer Biomarker Testing Solutions: Distribution by Type of Cancer
Figure 6.8 Cancer Biomarker Testing Solutions: Distribution by Application Area
Figure 6.9 Cancer Biomarker Testing Solution Providers: Distribution by Year of Establishment
Figure 6.10 Cancer Biomarker Testing Solution Providers: Distribution by Company Size
Figure 6.11 Cancer Biomarker Testing Solution Providers: Distribution by Location of Headquarters (Region)
Figure 7.1 Product Competitiveness Analysis: Cancer Biomarker Testing Solutions Offered by Players based in North America
Figure 7.2 Product Competitiveness Analysis: Cancer Biomarker Testing Solutions Offered by Players based in Europe
Figure 7.3 Product Competitiveness Analysis: Cancer Biomarker Testing Solutions Offered by Players based in Asia-Pacific
Figure 8.1 Agilent: Annual Revenues, FY 2019-FY 2023 (USD Million)
Figure 8.2 Thermo Fisher Scientific: Annual Revenues, FY 2019-FY 2023 (USD Million)
Figure 9.1 Enrichment Clinical Trial Design: Steps Involved
Figure 9.2 All-Comers Clinical Trial Design: Steps Involved
Figure 9.3 Hybrid Clinical Trial Design: Steps Involved
Figure 9.4 Adaptive Clinical Trial Design: Steps Involved
Figure 10.1 Clinical Trial Analysis: Distribution by Trial Registration Year, 2019-2023
Figure 10.2 Clinical Trial Analysis: Distribution by Trial Status
Figure 10.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, 2019-2023
Figure 10.4 Clinical Trial Analysis: Distribution by Trial Phase
Figure 10.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase, 2019-2023
Figure 10.6 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, 2019-2023
Figure 10.7 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 10.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 10.9 Clinical Trial Analysis: Distribution by Study Design
Figure 10.10 Clinical Trial Analysis: Distribution by Type of Cancer
Figure 10.11 Most Active Players: Distribution by Number of Registered Trials
Figure 10.12 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Figure 10.13 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Status and Geography
Figure 10.14 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography
Figure 10.15 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status and Geography
Figure 11.1 Publication Analysis: Cumulative Year-wise Trend of Publications, 2019-2023
Figure 11.2 Publication Analysis: Distribution by Type of Publication
Figure 11.3 Publication Analysis: Distribution by Type of Cancer
Figure 11.4 Most Popular Copyright Holders: Distribution by Number of Publications
Figure 11.5 Word Cloud Analysis: Emerging Focus Areas
Figure 11.6 Most Active Publishers: Distribution by Number of Publications
Figure 11.7 Key Journals: Distribution by Number of Publications
Figure 11.8 Key Journals: Distribution by Impact Factor
Figure 12.1 Spider Web Analysis: Abbott
Figure 12.2 Spider Web Analysis: AbbVie
Figure 12.3 Spider Web Analysis: Amgen
Figure 12.4 Spider Web Analysis: AstraZeneca
Figure 12.5 Spider Web Analysis: Bayer
Figure 12.6 Spider Web Analysis: Boehringer Ingelheim
Figure 12.7 Spider Web Analysis: Bristol-Myers Squib
Figure 12.8 Spider Web Analysis: Eli Lilly
Figure 12.9 Spider Web Analysis: Gilead
Figure 12.10 Spider Web Analysis: GlaxoSmithKline
Figure 12.11 Spider Web Analysis: Merck
Figure 12.12 Spider Web Analysis: Novartis
Figure 12.13 Spider Web Analysis: Pfizer
Figure 12.14 Spider Web Analysis: Roche
Figure 12.15 Spider Web Analysis: Sanofi
Figure 12.16 Benchmarking Analysis: Big Pharma players
Figure 13.1 Companion Diagnostics: Value Chain
Figure 13.2 Cost Distribution Across Value Chain
Figure 13.3 Costs Associated with Research and Product Development
Figure 13.4 Costs Associated with Manufacturing and Assembly
Figure 13.5 Costs Associated with Clinical Trials, FDA Approval and Other Administrative Tasks
Figure 13.6 Costs Associated with Payer Negotiation and KOL Engagement
Figure 13.7 Costs Associated with Marketing and Sales
Figure 14.1 Cancer Biomarkers Market: Future Growth Opportunities
Figure 15.1 Global Cancer Biomarkers Market, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 15.2 Global Cancer Biomarkers Market, Forecasted Estimates (2024-2035): Conservative Scenario (USD Billion)
Figure 15.3 Global Cancer Biomarkers Market, Forecasted Estimates (2024-2035): Optimistic Scenario (USD Billion)
Figure 16.1 Cancer Biomarkers Market: Distribution by Type of Biomarker, 2018, 2024 and 2035
Figure 16.2 Cancer Biomarkers Market for HER2 Biomarkers, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 16.3 Cancer Biomarkers Market for MET Biomarkers, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 16.4 Cancer Biomarkers Market for EGFR Biomarkers, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 16.5 Cancer Biomarkers Market for PD-L1 Biomarkers, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 16.6 Cancer Biomarkers Market for NTRK Biomarkers, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 16.7 Cancer Biomarkers Market for ALK Biomarkers, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 16.8 Cancer Biomarkers Market for Other Biomarkers, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 16.9 Cancer Biomarkers Market: Distribution of Novel Biomarkers, 2018, 2024 and 2035
Figure 16.10 Cancer Biomarkers Market for SNV Biomarkers, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 16.11 Cancer Biomarkers Market for MSI Biomarkers, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 16.12 Cancer Biomarkers Market for CNV Biomarkers, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 16.13 Cancer Biomarkers Market for TMB Biomarkers, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 16.14 Cancer Biomarkers Market for TIL Biomarkers, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 17.1 Cancer Biomarkers Market: Distribution by Type of Cancer, 2018, 2024 and 2035
Figure 17.2 Cancer Biomarkers Market for Breast Cancer, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 17.3 Cancer Biomarkers Market for Prostate Cancer, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 17.4 Cancer Biomarkers Market for Colorectum Cancer, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 17.5 Cancer Biomarkers Market for Lung Cancer, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 17.6 Cancer Biomarkers Market for Thyroid Cancer, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 17.7 Cancer Biomarkers Market for Bladder Cancer, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 17.8 Cancer Biomarkers Market for Melanoma, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 17.9 Cancer Biomarkers Market for Non-Hodgkin Lymphoma, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 17.10 Cancer Biomarkers Market for Endometrial Cancer, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 17.11 Cancer Biomarkers Market for Kidney Cancer, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 17.12 Cancer Biomarkers Market for Leukemia, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.1 Cancer Biomarkers Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035
Figure 18.2 Cancer Biomarkers Market in North America, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.3 Cancer Biomarkers Market in the US, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.4 Cancer Biomarkers Market in Canada, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.5 Cancer Biomarkers Market in Europe, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.6 Cancer Biomarkers Market in the UK, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.7 Cancer Biomarkers Market in Germany, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.8 Cancer Biomarkers Market in France, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.9 Cancer Biomarkers Market in Spain, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.10 Cancer Biomarkers Market in Italy, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.11 Cancer Biomarkers Market in Asia-Pacific, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.12 Cancer Biomarkers Market in China, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.13 Cancer Biomarkers Market in Japan, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.14 Cancer Biomarkers Market in India, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.15 Cancer Biomarkers Market in Australia, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.16 Cancer Biomarkers Market in South Korea, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.17 Cancer Biomarkers Market in New Zealand, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.18 Cancer Biomarkers Market in Rest of the World, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.19 Cancer Biomarkers Market in Brazil, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.20 Cancer Biomarkers Market in Argentina, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.21 Cancer Biomarkers Market in Chile, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.22 Cancer Biomarkers Market in Egypt, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 19.1 Concluding Remarks: Market Landscape
Figure 19.2 Concluding Remarks: Clinical Trial Analysis
Figure 19.3 Concluding Remarks: Publication Analysis
Figure 19.4 Concluding Remarks: Market Forecast and Opportunity Analysis

LIST OF TABLES
Table 6.1 Cancer Biomarkers Testing Solutions: Information on Type of Biomarkers
Table 6.2 Cancer Biomarkers Testing Solutions: Information on Profiling Technologies and Analytical Technique
Table 6.3 Cancer Biomarkers Testing Solutions: Information on Turnaround Time, Sample Input and Type of Nucleic Acid Tested
Table 6.4 Cancer Biomarkers Testing Solutions: Information on Type of Cancer
Table 6.5 Cancer Biomarkers Testing Solutions: Information on Application Area and End Users
Table 6.6 List of Cancer Biomarker Testing Solution Providers
Table 8.1 Cancer Biomarkers Testing Solution Providers: List of Companies Profiled
Table 8.2 Agilent: Company Overview
Table 8.3 Agilent: Cancer Biomarkers Testing Solutions Portfolio
Table 8.4 Agilent: Recent Developments and Future Outlook
Table 8.5 ARUP Laboratories: Company Overview
Table 8.6 ARUP Laboratories: Cancer Biomarker Testing Solutions Portfolio
Table 8.7 ARUP Laboratories: Recent Developments and Future Outlook
Table 8.8 BioReference: Company Overview
Table 8.9 BioReference: Cancer Biomarker Testing Solutions Portfolio
Table 8.10 BioReference: Recent Developments and Future Outlook
Table 8.11 Foundation Medicine: Company Overview
Table 8.12 Foundation Medicine: Cancer Biomarker Testing Solutions Portfolio
Table 8.13 Foundation Medicine: Recent Developments and Future Outlook
Table 8.14 OncoDNA: Company Overview
Table 8.15 OncoDNA: Cancer Biomarker Testing Solutions Portfolio
Table 8.16 OncoDNA: Recent Developments and Future Outlook
Table 8.17 Q² Solutions: Company Overview
Table 8.18 Q² Solutions: Cancer Biomarker Testing Solutions Portfolio
Table 8.19 Q² Solutions: Recent Developments and Future Outlook
Table 8.20 Thermo Fisher Scientific: Company Overview
Table 8.21 Thermo Fisher Scientific: Cancer Biomarker Testing Solutions Portfolio
Table 8.22 Thermo Fisher Scientific: Recent Developments and Future Outlook
Table 8.23 YuceBio: Company Overview
Table 8.24 YuceBio: Cancer Biomarker Testing Solutions Portfolio
Table 8.25 Asper Biogene: Company Overview
Table 8.26 Asper Biogene: Cancer Biomarkers Testing Solutions Portfolio
Table 8.27 Caris Life Sciences: Company Overview
Table 8.28 Caris Life Sciences: Cancer Biomarkers Testing Solutions Portfolio
Table 8.29 CeGaT: Company Overview
Table 8.30 CeGaT: Cancer Biomarkers Testing Solutions Portfolio
Table 8.31 Genekor Medical: Company Overview
Table 8.32 Genekor Medical: Cancer Biomarkers Testing Solutions Portfolio
Table 8.33 Guardant Health: Company Overview
Table 8.34 Guardant Health: Cancer Biomarkers Testing Solutions Portfolio
Table 8.35 Labcorp: Company Overview
Table 8.36 Labcorp: Cancer Biomarkers Testing Solutions Portfolio
Table 8.37 MedGenome: Company Overview
Table 8.38 MedGenome: Cancer Biomarkers Testing Solutions Portfolio
Table 8.39 NeoGenomics Laboratories: Company Overview
Table 8.40 NeoGenomics Laboratories: Cancer Biomarkers Testing Solutions Portfolio
Table 8.41 Nonacus: Company Overview
Table 8.42 Nonacus: Cancer Biomarkers Testing Solutions Portfolio
Table 8.43 Oxford Gene Technology: Company Overview
Table 8.44 Oxford Gene Technology: Cancer Biomarkers Testing Solutions Portfolio
Table 8.45 Personal Genome Diagnostics: Company Overview
Table 8.46 Personal Genome Diagnostics: Cancer Biomarkers Testing Solutions Portfolio
Table 8.47 PhenoPath: Company Overview
Table 8.48 PhenoPath: Cancer Biomarkers Testing Solutions Portfolio
Table 8.49 Positive Biosciences: Company Overview
Table 8.50 Positive Biosciences: Cancer Biomarkers Testing Solutions Portfolio
Table 8.51 Quest Diagnostics: Company Overview
Table 8.52 Quest Diagnostics: Cancer Biomarkers Testing Solutions Portfolio
Table 8.53 Tempus: Company Overview
Table 8.54 Tempus: Cancer Biomarkers Testing Solutions Portfolio
Table 20.1 Cell IDx: Company Snapshot
Table 20.2 CeGat: Company Snapshot
Table 20.3 NeoGenomics Laboratories: Company Snapshot
Table 21.1 Cancer Biomarker Testing Solutions: Distribution by Type of Biomarker
Table 21.2 Cancer Biomarker Testing Solutions: Distribution by Profiling Technology Used
Table 21.3 Cancer Biomarker Testing Solutions: Distribution by Analytical Technique Used
Table 21.4 Cancer Biomarker Testing Solutions: Distribution by Turnaround Time
Table 21.5 Cancer Biomarker Testing Solutions: Distribution by Sample Input
Table 21.6 Cancer Biomarker Testing Solutions: Distribution by Type of Nucleic Acid Tested
Table 21.7 Cancer Biomarker Testing Solutions: Distribution by Type of Cancer
Table 21.8 Cancer Biomarker Testing Solutions: Distribution by Application Area
Table 21.9 Cancer Biomarker Testing Solution Providers: Distribution by Year of Establishment
Table 21.10 Cancer Biomarker Testing Solution Providers: Distribution by Company Size
Table 21.11 Cancer Biomarker Testing Solution Providers: Distribution by Location of Headquarters (Region)
Table 21.12 Agilent: Annual Revenues, FY 2019-FY 2023 (USD Million)
Table 21.13 Thermo Fisher Scientific: Annual Revenues, FY 2019-FY 2023 (USD Million)
Table 21.14 Clinical Trial Analysis: Distribution by Trial Registration Year, 2019-2023
Table 21.15 Clinical Trial Analysis: Distribution by Trial Status
Table 21.16 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, 2019-2023
Table 21.17 Clinical Trial Analysis: Distribution by Trial Phase
Table 21.18 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase, 2019-2023
Table 21.19 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, 2019-2023
Table 21.20 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Table 21.21 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 21.22 Clinical Trial Analysis: Distribution by Study Design
Table 21.23 Clinical Trial Analysis: Distribution by Type of Cancer
Table 21.24 Most Active Players: Distribution by Number of Registered Trials
Table 21.25 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Table 21.26 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Status and Geography
Table 21.27 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography
Table 21.28 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status and Geography
Table 21.29 Publication Analysis: Cumulative Year-wise Trend of Publications, 2019-2023
Table 21.30 Publication Analysis: Distribution by Type of Publication
Table 21.31 Publication Analysis: Distribution by Type of Cancer
Table 21.32 Most Popular Copyright Holders: Distribution by Number of Publications
Table 21.33 Most Active Publishers: Distribution by Number of Publications
Table 21.34 Key Journals: Distribution by Number of Publications
Table 21.35 Key Journals: Distribution by Impact Factor
Table 21.36 Benchmarking Analysis: Big Pharma players
Table 21.37 Global Cancer Biomarkers Market, Historical Trends (2018-2023) (USD Billion)
Table 21.38 Global Cancer Biomarkers Market, Forecasted Estimates (2024-2035) Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.39 Cancer Biomarkers Market: Distribution by Type of Biomarker, 2018, 2024 and 2035 (USD Billion)
Table 21.40 Cancer Biomarkers Market for HER2 Biomarkers: Historical Trends (2018-2023) (USD Billion)
Table 21.41 Cancer Biomarkers Market for HER2 Biomarkers: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.42 Cancer Biomarkers Market for MET Biomarkers: Historical Trends (2018-2023) (USD Billion)
Table 21.43 Cancer Biomarkers Market for MET Biomarkers: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.44 Cancer Biomarkers Market for EGFR Biomarkers: Historical Trends (2018-2023) (USD Billion)
Table 21.45 Cancer Biomarkers Market for EGFR Biomarkers: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.46 Cancer Biomarkers Market for PD-L1 Biomarkers: Historical Trends (2018-2023) (USD Billion)
Table 21.47 Cancer Biomarkers Market for PD-L1 Biomarkers: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.48 Cancer Biomarkers Market for NTRK Biomarkers: Historical Trends (2018-2023) (USD Billion)
Table 21.49 Cancer Biomarkers Market for NTRK Biomarkers: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.50 Cancer Biomarkers Market for ALK Biomarkers: Historical Trends (2018-2023) (USD Billion)
Table 21.51 Cancer Biomarkers Market for ALK Biomarkers: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.52 Cancer Biomarkers Market for Other Biomarkers: Historical Trends (2018-2023) (USD Billion)
Table 21.53 Cancer Biomarkers Market for Other Biomarkers: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.54 Cancer Biomarkers Market: Distribution of Novel Biomarkers, 2018, 2024 and 2035 (USD Billion)
Table 21.55 Cancer Biomarkers Market for SNV Biomarkers: Historical Trends (2018-2023) (USD Billion)
Table 21.56 Cancer Biomarkers Market for SNV Biomarkers: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.57 Cancer Biomarkers Market for MSI Biomarkers: Historical Trends (2018-2023) (USD Billion)
Table 21.58 Cancer Biomarkers Market for MSI Biomarkers: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.59 Cancer Biomarkers Market for CNV Biomarkers: Historical Trends (2018-2023) (USD Billion)
Table 21.60 Cancer Biomarkers Market for CNV Biomarkers: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.61 Cancer Biomarkers Market for TMB Biomarkers: Historical Trends (2018-2023) (USD Billion)
Table 21.62 Cancer Biomarkers Market for TMB Biomarkers: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.63 Cancer Biomarkers Market for TIL Biomarkers: Historical Trends (2018-2023) (USD Billion)
Table 21.64 Cancer Biomarkers Market for TIL Biomarkers: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.65 Cancer Biomarkers Market: Distribution by Type of Cancer, 2018, 2024 and 2035 (USD Billion)
Table 21.66 Cancer Biomarkers Market for Breast Cancer: Historical Trends (2018-2023) (USD Billion)
Table 21.67 Cancer Biomarkers Market for Breast Cancer: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.68 Cancer Biomarkers Market for Prostate Cancer: Historical Trends (2018-2023) (USD Billion)
Table 21.69 Cancer Biomarkers Market for Prostate Cancer: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.70 Cancer Biomarkers Market for Colorectum Cancer: Historical Trends (2018-2023) (USD Billion)
Table 21.71 Cancer Biomarkers Market for Colorectum Cancer: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.72 Cancer Biomarkers Market for Lung Cancer: Historical Trends (2018-2023) (USD Billion)
Table 21.73 Cancer Biomarkers Market for Lung Cancer: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.74 Cancer Biomarkers Market for Thyroid Cancer: Historical Trends (2018-2023) (USD Billion)
Table 21.75 Cancer Biomarkers Market for Thyroid Cancer: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.76 Cancer Biomarkers Market for Bladder Cancer: Historical Trends (2018-2023) (USD Billion)
Table 21.77 Cancer Biomarkers Market for Bladder Cancer: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.78 Cancer Biomarkers Market for Melanoma: Historical Trends (2018-2023) (USD Billion)
Table 21.79 Cancer Biomarkers Market for Melanoma: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.80 Cancer Biomarkers Market for Non-Hodgkin Lymphoma: Historical Trends (2018-2023) (USD Billion)
Table 21.81 Cancer Biomarkers Market for Non-Hodgkin Lymphoma: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.82 Cancer Biomarkers Market for Endometrial Cancer: Historical Trends (2018-2023) (USD Billion)
Table 21.83 Cancer Biomarkers Market for Endometrial Cancer: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.84 Cancer Biomarkers Market for Kidney Cancer: Historical Trends (2018-2023) (USD Billion)
Table 21.85 Cancer Biomarkers Market for Kidney Cancer: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.86 Cancer Biomarkers Market for Leukemia: Historical Trends (2018-2023) (USD Billion)
Table 21.87 Cancer Biomarkers Market for Leukemia: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.88 Cancer Biomarkers Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035 (USD Billion)
Table 21.89 Cancer Biomarkers Market in North America: Historical Trends (2018-2023) (USD Billion)
Table 21.90 Cancer Biomarkers Market in North America: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.91 Cancer Biomarkers Market in the US: Historical Trends (2018-2023) (USD Billion)
Table 21.92 Cancer Biomarkers Market in the US: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.93 Cancer Biomarkers Market in Canada: Historical Trends (2018-2023) (USD Billion)
Table 21.94 Cancer Biomarkers Market in Canada: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.95 Cancer Biomarkers Market in Europe: Historical Trends (2018-2023) (USD Billion)
Table 21.96 Cancer Biomarkers Market in Europe: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.97 Cancer Biomarkers Market in the UK: Historical Trends (2018-2023) (USD Billion)
Table 21.98 Cancer Biomarkers Market in the UK: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.99 Cancer Biomarkers Market in Germany: Historical Trends (2018-2023) (USD Billion)
Table 21.100 Cancer Biomarkers Market in Germany: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.101 Cancer Biomarkers Market in France: Historical Trends (2018-2023) (USD Billion)
Table 21.102 Cancer Biomarkers Market in France: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.103 Cancer Biomarkers Market in Spain: Historical Trends (2018-2023) (USD Billion)
Table 21.104 Cancer Biomarkers Market in Spain: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.105 Cancer Biomarkers Market in Italy: Historical Trends (2018-2023) (USD Billion)
Table 21.106 Cancer Biomarkers Market in Italy: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.107 Cancer Biomarkers Market in Asia-Pacific: Historical Trends (2018-2023) (USD Billion)
Table 21.108 Cancer Biomarkers Market in Asia-Pacific: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.109 Cancer Biomarkers Market in China: Historical Trends (2018-2023) (USD Billion)
Table 21.110 Cancer Biomarkers Market in China: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.111 Cancer Biomarkers Market in Japan: Historical Trends (2018-2023) (USD Billion)
Table 21.112 Cancer Biomarkers Market in Japan: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.113 Cancer Biomarkers Market in India: Historical Trends (2018-2023) (USD Billion)
Table 21.114 Cancer Biomarkers Market in India: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.115 Cancer Biomarkers Market in Australia: Historical Trends (2018-2023) (USD Billion)
Table 21.116 Cancer Biomarkers Market in Australia: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.117 Cancer Biomarkers Market in South Korea: Historical Trends (2018-2023) (USD Billion)
Table 21.118 Cancer Biomarkers Market in South Korea: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.119 Cancer Biomarkers Market in New Zealand: Historical Trends (2018-2023) (USD Billion)
Table 21.120 Cancer Biomarkers Market in New Zealand: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.121 Cancer Biomarkers Market in Rest of the World: Historical Trends (2018-2023) (USD Billion)
Table 21.122 Cancer Biomarkers Market in Rest of the World: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.123 Cancer Biomarkers Market in Brazil: Historical Trends (2018-2023) (USD Billion)
Table 21.124 Cancer Biomarkers Market in Brazil: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.125 Cancer Biomarkers Market in Argentina: Historical Trends (2018-2023) (USD Billion)
Table 21.126 Cancer Biomarkers Market in Argentina: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.127 Cancer Biomarkers Market in Chile: Historical Trends (2018-2023) (USD Billion)
Table 21.128 Cancer Biomarkers Market in Chile: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 21.129 Cancer Biomarkers Market in Egypt: Historical Trends (2018-2023) (USD Billion)
Table 21.130 Cancer Biomarkers Market in Egypt: Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenarios (USD Billion)

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Agilent
  • ARUP Laboratories
  • BioReference
  • Foundation Medicine
  • OncoDNA
  • Q² Solutions
  • Thermo Fisher Scientific
  • YuceBio
  • Asper Biogene
  • Caris Life Sciences
  • CeGaT
  • Genekor Medical
  • Guardant Health
  • Labcorp
  • MedGenome
  • NeoGenomics Laboratories
  • Nonacus
  • Oxford Gene Technology
  • Personal Genome Diagnostics
  • PhenoPath
  • Positive Biosciences
  • Quest Diagnostics
  • Tempus

Methodology

 

 

Loading
LOADING...

Related Topics

Related Reports

Cancer Biomarkers Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034 - Product Image

Cancer Biomarkers Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

  • Report
  • 138 Pages
  • Global
From
Prostate Cancer Biomarkers Market Size, Share & Trends Analysis Report by Type (Genetic Biomarkers, Cell-based Biomarkers, Metabolomic Biomarkers), Application, End-use, Region, with Growth Forecasts, 2025-2030 - Product Image

Prostate Cancer Biomarkers Market Size, Share & Trends Analysis Report by Type (Genetic Biomarkers, Cell-based Biomarkers, Metabolomic Biomarkers), Application, End-use, Region, with Growth Forecasts, 2025-2030

  • Report
  • 120 Pages
  • Global
From
Genetic Cancer Biomarkers - Global Strategic Business Report - Product Image

Genetic Cancer Biomarkers - Global Strategic Business Report

  • Report
  • 276 Pages
  • Global
From
Cancer Biomarkers Market Outlook Report: Industry Size, Market Shares Data, Latest Trends, Insights, Growth Potential, CAGR Forecasts to 2034 - Product Image

Cancer Biomarkers Market Outlook Report: Industry Size, Market Shares Data, Latest Trends, Insights, Growth Potential, CAGR Forecasts to 2034

  • Report
  • 150 Pages
  • Global
From
Cancer Biomarkers Market by Biomarker Type, Technology, Application, End User, Cancer Type, Test Type - Global Forecast to 2030 - Product Image

Cancer Biomarkers Market by Biomarker Type, Technology, Application, End User, Cancer Type, Test Type - Global Forecast to 2030

  • Report
  • 190 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.